Effect of S-equol and Soy Isoflavones on Heart and Brain

Curr Cardiol Rev. 2019;15(2):114-135. doi: 10.2174/1573403X15666181205104717.

Abstract

Background: Observational studies in Asia show that dietary intake of soy isoflavones had a significant inverse association with coronary heart disease (CHD). A recent randomized controlled trial (RCT) of soy isoflavones on atherosclerosis in the US, however, failed to show their benefit. The discrepancy may be due to the much lower prevalence of S-equol producers in Westerners: Only 20-30% of Westerners produce S-equol in contrast to 50-70% in Asians. S-equol is a metabolite of dietary soy isoflavone daidzein by gut microbiome and possesses the most antiatherogenic properties among all isoflavones. Several short-duration RCTs documented that soy isoflavones improves arterial stiffness. Accumulating evidence shows that both atherosclerosis and arterial stiffness are positively associated with cognitive decline/dementia. Therefore, potentially, soy isoflavones, especially S-equol, are protective against cognitive decline/dementia.

Methods/results: This narrative review of clinical and epidemiological studies provides an overview of the health benefits of soy isoflavones and introduces S-equol. Second, we review recent evidence on the association of soy isoflavones and S-equol with CHD, atherosclerosis, and arterial stiffness as well as the association of atherosclerosis and arterial stiffness with cognitive decline/ dementia. Third, we highlight recent studies that report the association of soy isoflavones and S-equol with cognitive decline/dementia. Lastly, we discuss the future directions of clinical and epidemiological research on the relationship of S-equol and CHD and dementia.

Conclusions: Evidence from observational studies and short-term RCTs suggests that S-equol is anti-atherogenic and improves arterial stiffness and may prevent CHD and cognitive impairment/ dementia. Well-designed long-term (≥ 2years) RCTs should be pursued.

Keywords: S-equol; arterial stiffness; atherosclerosis; cognitive impairment; cognitive decline; coronary heart disease; dementia; soy isoflavones..

Publication types

  • Review

MeSH terms

  • Aged
  • Brain / physiopathology*
  • Coronary Disease / diet therapy*
  • Coronary Disease / pathology
  • Diet / methods*
  • Equol / chemistry*
  • Female
  • Glycine max / chemistry*
  • Heart / physiopathology*
  • Humans
  • Isoflavones / chemistry*
  • Male
  • Middle Aged

Substances

  • Isoflavones
  • Equol